These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 33358592)
1. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus. Viúdez A; Crespo G; Gómez Dorronsoro ML; Arozarena I; Marín-Méndez JJ; Custodio A; Benavent M; Goñi S; García-Paredes B; Hernando J; Durantez M; Alonso V; Riesco MDC; López C; Jiménez-Fonseca P; San Vicente BL; González-Borja I; Sevilla I; Hernández-Garcia I; Carmona-Bayonas A; Capdevila J; Pérez-Sanz J; García-Carbonero R; Pérez-Ricarte L; Llanos M; Vera R; De Jesús Acosta A Pancreatology; 2021 Jan; 21(1):215-223. PubMed ID: 33358592 [TBL] [Abstract][Full Text] [Related]
2. A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET). Viúdez A; Carvalho FL; Maleki Z; Zahurak M; Laheru D; Stark A; Azad NS; Wolfgang CL; Baylin S; Herman JG; De Jesus-Acosta A Oncotarget; 2016 May; 7(18):24950-61. PubMed ID: 26894863 [TBL] [Abstract][Full Text] [Related]
3. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors. Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619 [TBL] [Abstract][Full Text] [Related]
4. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. Raj N; Klimstra DS; Horvat N; Zhang L; Chou JF; Capanu M; Basturk O; Do RKG; Allen PJ; Reidy-Lagunes D Pancreas; 2017 Jul; 46(6):758-763. PubMed ID: 28609363 [TBL] [Abstract][Full Text] [Related]
5. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Cives M; Ghayouri M; Morse B; Brelsford M; Black M; Rizzo A; Meeker A; Strosberg J Endocr Relat Cancer; 2016 Sep; 23(9):759-67. PubMed ID: 27552969 [TBL] [Abstract][Full Text] [Related]
6. Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. Campana D; Walter T; Pusceddu S; Gelsomino F; Graillot E; Prinzi N; Spallanzani A; Fiorentino M; Barritault M; Dall'Olio F; Brighi N; Biasco G Endocrine; 2018 Jun; 60(3):490-498. PubMed ID: 29150792 [TBL] [Abstract][Full Text] [Related]
8. O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET). Lemelin A; Barritault M; Hervieu V; Payen L; Péron J; Couvelard A; Cros J; Scoazec JY; Bin S; Villeneuve L; Lombard-Bohas C; Walter T; Dig Liver Dis; 2019 Apr; 51(4):595-599. PubMed ID: 30824408 [TBL] [Abstract][Full Text] [Related]
9. Expression of O(6)-methylguanine DNA methyltransferase (MGMT) and its clinical significance in gastroenteropancreatic neuroendocrine neoplasm. Yang QC; Wang YH; Lin Y; Xue L; Chen YJ; Chen MH; Chen J Int J Clin Exp Pathol; 2014; 7(7):4204-12. PubMed ID: 25120800 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors. Squires MH; Worth PJ; Konda B; Shah MH; Dillhoff ME; Abdel-Misih S; Norton JA; Visser BC; Dua M; Pawlik TM; Schmidt CR; Poultsides G; Cloyd JM Pancreas; 2020 Mar; 49(3):355-360. PubMed ID: 32132509 [TBL] [Abstract][Full Text] [Related]
11. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Chan JA; Blaszkowsky L; Stuart K; Zhu AX; Allen J; Wadlow R; Ryan DP; Meyerhardt J; Gonzalez M; Regan E; Zheng H; Kulke MH Cancer; 2013 Sep; 119(17):3212-8. PubMed ID: 23733618 [TBL] [Abstract][Full Text] [Related]
12. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594 [TBL] [Abstract][Full Text] [Related]
13. Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET. Hijioka S; Sakuma K; Aoki M; Mizuno N; Kuwahara T; Okuno N; Hara K; Yatabe Y Cancer Chemother Pharmacol; 2019 Jan; 83(1):43-52. PubMed ID: 30310970 [TBL] [Abstract][Full Text] [Related]
14. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102 [TBL] [Abstract][Full Text] [Related]
15. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors. Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359 [TBL] [Abstract][Full Text] [Related]
16. Should temozolomide be used on the basis of O Trillo Aliaga P; Spada F; Peveri G; Bagnardi V; Fumagalli C; Laffi A; Rubino M; Gervaso L; Guerini Rocco E; Pisa E; Curigliano G; Fazio N Cancer Treat Rev; 2021 Sep; 99():102261. PubMed ID: 34332293 [TBL] [Abstract][Full Text] [Related]
17. Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors. Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Ni Q; Wang W; Liu L Endocr Pract; 2022 Mar; 28(3):292-297. PubMed ID: 34454077 [TBL] [Abstract][Full Text] [Related]
18. Proteins of the retinoblastoma pathway, FEN1 and MGMT are novel potential prognostic biomarkers in pancreatic adenocarcinoma. Isohookana J; Haapasaari KM; Soini Y; Leppänen J; Karihtala P Pathol Res Pract; 2018 Jun; 214(6):840-847. PubMed ID: 29735403 [TBL] [Abstract][Full Text] [Related]
19. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors. Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818 [TBL] [Abstract][Full Text] [Related]
20. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Lombard-Bohas C; Yao JC; Hobday T; Van Cutsem E; Wolin EM; Panneerselvam A; Stergiopoulos S; Shah MH; Capdevila J; Pommier R Pancreas; 2015 Mar; 44(2):181-9. PubMed ID: 25479584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]